Belgium Data Desk › Health › Evaluation of the new medication Kalydeco to treat cystic fibrosis
Evaluation of the new medication Kalydeco to treat cystic fibrosis
Kalydeco is a medicine for the treatment of cystic fibrosis (CF) patients. This medicine is only for CF patients with a specific genetic mutation on the CFTR gene: G551D, G1244E, G1349R G178R, G551S, S1251N, S1255P, S549N or S549R. On 26/11/2015, the manufacturer of Kalydeco, Vertex Pharmaceuticals, and the NIHDI signe
- Publisher
- Vertex Pharmaceuticals
- Licence
- ODC-BY
Open licence — reuse allowed, usually with attribution - Topic
- Health
- Type
- Dataset
- Last updated (catalogue)
- 2026-08-11
- Update cycle
- continuous
- Formats
- CSV, JSON, HTML
- Contact
- vertexmedicalinfo@vrtx.com
Open in Belgium Data DeskPreview, profile and run SQL in your browser
Official page at the publisher ↗
Download link checked on 2026-10-04: 3 of 3 worked. This page describes catalogue information. It does not state that the data is correct.
More in this topic
- ATMO-Street annual high-resolution model outputsBelgian Interregional Environment Agency · No licence stated in the catalogue
- NomenSoft coordinated reference tablesRIZIV / INAMI · No licence stated in the catalogue
- NomenSoft update filesRIZIV / INAMI · No licence stated in the catalogue
- PM10 rolling 24h mean — station featuresBelgian Interregional Environment Agency · No licence stated in the catalogue
- RIO annual/daily results by communeBelgian Interregional Environment Agency · No licence stated in the catalogue